Evaluation of NSCLC Cytology Cell Block Specimens Using Ventana PD-L1 SP263 Immunohistochemistry Assay

被引：0
|
作者：
Chauhan, Aastha [1 ]
Racila, Emilian [2 ]
Stewart, Jimmie [3 ]
Amin, Khalid [3 ]
机构：
[1] Univ Minnesota, St Paul, MN 55108 USA
[2] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Minneapolis, MN USA
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
335
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluation of NSCLC Cytology Cell Block Specimens Using Ventana PD-L1 SP263 Immunohistochemistry Assay
    Chauhan, Aastha
    Racila, Emilian
    Stewart, Jimmie
    Amin, Khalid
    MODERN PATHOLOGY, 2019, 32
  • [2] Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay.
    Scott, Marietta L.
    Scorer, Paul
    Lawson, Nicola
    Ratcliffe, Marianne J.
    Barker, Craig
    Rebelatto, Marlon
    Walker, Jill
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC
    Williams, Gareth H.
    Nicholson, Andrew G.
    Snead, David R. J.
    Thunnissen, Erik
    Lantuejoul, Sylvie
    Cane, Paul
    Kerr, Keith M.
    Loddo, Marco
    Scott, Marietta L. J.
    Scorer, Paul W.
    Barker, Craig
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 550 - 555
  • [4] Validation of VENTANA (SP263) PD-L1 immunohistochemistry (IHC) assay in formalin-fixed, paraffin embedded (FFPE) cytology samples
    Barker, C.
    Horne, H.
    Scorer, P.
    Roland, B.
    Hayden, D.
    Schnittker, K.
    VIRCHOWS ARCHIV, 2021, 479 : S158 - S159
  • [5] Validation Study of Ventana SP263 PD-L1 Immunohistochemistry Antibody Assay as LDT for Clinical Use in patients with NSCLC being considered for Keytruda Therapy
    Marolt, Monna
    Racila, Emilian
    MODERN PATHOLOGY, 2019, 32
  • [6] Validation Study of Ventana SP263 PD-L1 Immunohistochemistry Antibody Assay as LDT for Clinical Use in patients with NSCLC being considered for Keytruda Therapy
    Marolt, Monna
    Racila, Emilian
    LABORATORY INVESTIGATION, 2019, 99
  • [7] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
    Nielsen, Alma
    Manriquez, Guadalupe
    Hayden, Dorothy
    Lian, Fangru
    Liu, Chunyan
    Patil, Pallavi
    Wang, Peiyi
    Gu, Pengfei
    Schnittker, Karina
    Roland, Bryan
    Quiroz, Michelle
    Newell, Amy Hanlon
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 830 - 831
  • [8] Precision and Repeatability of the VENTANA PD-L1 (SP263) Assay Across Six Different Tumor Types
    Nielsen, Alma
    Manriquez, Guadalupe
    Hayden, Dorothy
    Lian, Fangru
    Liu, Chunyan
    Patil, Pallavi
    Wang, Peiyi
    Gu, Pengfei
    Schnittker, Karina
    Roland, Bryan
    Quiroz, Michelle
    Newell, Amy Hanlon
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 830 - 831
  • [9] Inter-rater reliability of programmed death ligand 1 ( PD-L1) scoring using the VENTANA PD-L1 (SP263) assay in non-small cell lung cancer (NSCLC)
    Williams, G. H.
    Nicholson, A. G.
    Snead, D. R. J.
    Thunnissen, E.
    Lantuejoul, S.
    Cane, P.
    Kerr, K. M.
    Loddo, M.
    Scott, M.
    Scorer, P. W.
    Barker, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS)
    Chao, Y.
    Yang, S.
    Zhang, Y.
    Shen, Z.
    Wu, X.
    Wang, J.
    Quiroz, M.
    Nielsen, A.
    Liu, C.
    Desai, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S300 - S300
12345